RET is a Heat Shock Protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block

Luigi Alfano, Teresa Guida, Livia Provitera, Giancarlo Vecchio, Marc Billaud, Massimo Santoro, Francesca Carlomagno

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Context: Mutations of the RET receptor tyrosine kinase are associated to multiple endocrine neoplasia type 2 (MEN2)and sporadic medullary thyroid carcinoma (MTC). The heat shock protein (HSP) 90 chaperone is required for folding and stability of several kinases. HSP90 is specifically inhibited by 17-allyl-amino-17-demethoxygeldanamycin (17-AAG). Objective: Our aim was to investigate whether RET protein half-life depends on HSP90 and to dissect the molecular pathway responsible for the degradation of RET upon HSP90 inhibition by 17-AAG. Design: 17-AAG effects were studied in RAT1 fibroblasts exogenously expressing MEN2-associated RET mutants and human MTC-derived cell lines. Results: 17-AAG induced a 26S proteasome-dependent degradation of wild-type RET and MEN2-associated RET mutants. The compound hampered HSP90/RET interaction and stabilized RET binding to HSP70, leading to the recruitment of the HSP70-associated E3 ligase C-terminus of Hsc70-interacting protein. In turn, C-terminus of Hsc70-interacting protein polyubiquitinated RET, promoting its proteasomal degradation. 17-AAG blocked RET downstream effectors and RET-dependent transcriptional activation of gene promoters. In human MTC cells carrying oncogenic RET mutants, HSP90 inhibition induced receptor degradation and signaling hindrance leading to cell cycle arrest. Conclusion: RET and MEN2-associated RET mutants rely on HSP90 for protein stability, and HSP90 blockade by 17-AAG promotes RET degradation.

Original languageEnglish
Pages (from-to)3552-3557
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume95
Issue number7
DOIs
Publication statusPublished - Jul 2010

Fingerprint

HSP90 Heat-Shock Proteins
Pharmacology
Multiple Endocrine Neoplasia Type 2a
Proteins
Degradation
HSC70 Heat-Shock Proteins
Proto-Oncogene Proteins c-ret
Cells
Ubiquitin-Protein Ligases
Protein Stability
Fibroblasts
Cell Cycle Checkpoints
Transcriptional Activation
Half-Life
Phosphotransferases
Genes
Chemical activation
Cell Line
Mutation

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

RET is a Heat Shock Protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block. / Alfano, Luigi; Guida, Teresa; Provitera, Livia; Vecchio, Giancarlo; Billaud, Marc; Santoro, Massimo; Carlomagno, Francesca.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 95, No. 7, 07.2010, p. 3552-3557.

Research output: Contribution to journalArticle

Alfano, Luigi ; Guida, Teresa ; Provitera, Livia ; Vecchio, Giancarlo ; Billaud, Marc ; Santoro, Massimo ; Carlomagno, Francesca. / RET is a Heat Shock Protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block. In: Journal of Clinical Endocrinology and Metabolism. 2010 ; Vol. 95, No. 7. pp. 3552-3557.
@article{7a14c18a06ee4fe9a3d7d3fd4d59fe73,
title = "RET is a Heat Shock Protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block",
abstract = "Context: Mutations of the RET receptor tyrosine kinase are associated to multiple endocrine neoplasia type 2 (MEN2)and sporadic medullary thyroid carcinoma (MTC). The heat shock protein (HSP) 90 chaperone is required for folding and stability of several kinases. HSP90 is specifically inhibited by 17-allyl-amino-17-demethoxygeldanamycin (17-AAG). Objective: Our aim was to investigate whether RET protein half-life depends on HSP90 and to dissect the molecular pathway responsible for the degradation of RET upon HSP90 inhibition by 17-AAG. Design: 17-AAG effects were studied in RAT1 fibroblasts exogenously expressing MEN2-associated RET mutants and human MTC-derived cell lines. Results: 17-AAG induced a 26S proteasome-dependent degradation of wild-type RET and MEN2-associated RET mutants. The compound hampered HSP90/RET interaction and stabilized RET binding to HSP70, leading to the recruitment of the HSP70-associated E3 ligase C-terminus of Hsc70-interacting protein. In turn, C-terminus of Hsc70-interacting protein polyubiquitinated RET, promoting its proteasomal degradation. 17-AAG blocked RET downstream effectors and RET-dependent transcriptional activation of gene promoters. In human MTC cells carrying oncogenic RET mutants, HSP90 inhibition induced receptor degradation and signaling hindrance leading to cell cycle arrest. Conclusion: RET and MEN2-associated RET mutants rely on HSP90 for protein stability, and HSP90 blockade by 17-AAG promotes RET degradation.",
author = "Luigi Alfano and Teresa Guida and Livia Provitera and Giancarlo Vecchio and Marc Billaud and Massimo Santoro and Francesca Carlomagno",
year = "2010",
month = "7",
doi = "10.1210/jc.2009-2315",
language = "English",
volume = "95",
pages = "3552--3557",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - RET is a Heat Shock Protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block

AU - Alfano, Luigi

AU - Guida, Teresa

AU - Provitera, Livia

AU - Vecchio, Giancarlo

AU - Billaud, Marc

AU - Santoro, Massimo

AU - Carlomagno, Francesca

PY - 2010/7

Y1 - 2010/7

N2 - Context: Mutations of the RET receptor tyrosine kinase are associated to multiple endocrine neoplasia type 2 (MEN2)and sporadic medullary thyroid carcinoma (MTC). The heat shock protein (HSP) 90 chaperone is required for folding and stability of several kinases. HSP90 is specifically inhibited by 17-allyl-amino-17-demethoxygeldanamycin (17-AAG). Objective: Our aim was to investigate whether RET protein half-life depends on HSP90 and to dissect the molecular pathway responsible for the degradation of RET upon HSP90 inhibition by 17-AAG. Design: 17-AAG effects were studied in RAT1 fibroblasts exogenously expressing MEN2-associated RET mutants and human MTC-derived cell lines. Results: 17-AAG induced a 26S proteasome-dependent degradation of wild-type RET and MEN2-associated RET mutants. The compound hampered HSP90/RET interaction and stabilized RET binding to HSP70, leading to the recruitment of the HSP70-associated E3 ligase C-terminus of Hsc70-interacting protein. In turn, C-terminus of Hsc70-interacting protein polyubiquitinated RET, promoting its proteasomal degradation. 17-AAG blocked RET downstream effectors and RET-dependent transcriptional activation of gene promoters. In human MTC cells carrying oncogenic RET mutants, HSP90 inhibition induced receptor degradation and signaling hindrance leading to cell cycle arrest. Conclusion: RET and MEN2-associated RET mutants rely on HSP90 for protein stability, and HSP90 blockade by 17-AAG promotes RET degradation.

AB - Context: Mutations of the RET receptor tyrosine kinase are associated to multiple endocrine neoplasia type 2 (MEN2)and sporadic medullary thyroid carcinoma (MTC). The heat shock protein (HSP) 90 chaperone is required for folding and stability of several kinases. HSP90 is specifically inhibited by 17-allyl-amino-17-demethoxygeldanamycin (17-AAG). Objective: Our aim was to investigate whether RET protein half-life depends on HSP90 and to dissect the molecular pathway responsible for the degradation of RET upon HSP90 inhibition by 17-AAG. Design: 17-AAG effects were studied in RAT1 fibroblasts exogenously expressing MEN2-associated RET mutants and human MTC-derived cell lines. Results: 17-AAG induced a 26S proteasome-dependent degradation of wild-type RET and MEN2-associated RET mutants. The compound hampered HSP90/RET interaction and stabilized RET binding to HSP70, leading to the recruitment of the HSP70-associated E3 ligase C-terminus of Hsc70-interacting protein. In turn, C-terminus of Hsc70-interacting protein polyubiquitinated RET, promoting its proteasomal degradation. 17-AAG blocked RET downstream effectors and RET-dependent transcriptional activation of gene promoters. In human MTC cells carrying oncogenic RET mutants, HSP90 inhibition induced receptor degradation and signaling hindrance leading to cell cycle arrest. Conclusion: RET and MEN2-associated RET mutants rely on HSP90 for protein stability, and HSP90 blockade by 17-AAG promotes RET degradation.

UR - http://www.scopus.com/inward/record.url?scp=77954948471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954948471&partnerID=8YFLogxK

U2 - 10.1210/jc.2009-2315

DO - 10.1210/jc.2009-2315

M3 - Article

VL - 95

SP - 3552

EP - 3557

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -